Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.01
1% from low
Exchange
OTC Link
CS
Borrow rate
0.25%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $680.0K | $0 | $0 | $76.2K | $252.0K | $0 | $0 | $0 |
| Cost of revenue | $0 | $49.2K | $450.9K | $284.0K | $409.0K | $0 | $0 | $0 |
| Gross profit | $680.0K | −$49.2K | −$451.0K | −$383.0K | −$157.0K | $0 | $0 | $0 |
| Gross margin | 100.0% | — | — | -502.7% | -62.3% | — | — | — |
| R&D | $801.0K | $108.9K | $907.5K | $241.0K | $0 | $0 | $0 | $0 |
| Operating income | −$4.0M | −$758.0K | −$6.1M | −$15.8M | −$11.3M | −$2.0M | −$674.0K | −$1.6M |
| EBITDA | $3.3M | −$709.0K | −$5.6M | −$16.3M | −$11.2M | −$1.6M | −$674.0K | −$1.6M |
| Net income | $3.3M | −$837.0K | −$6.2M | −$16.8M | −$12.0M | −$3.8M | −$6.4M | −$2.1M |
| Net margin | 490.7% | — | — | -21992.2% | -4753.2% | — | — | — |
| EPS (diluted) | -28.00 | -3.53 | -12.65 | -32.80 | -24.80 | -9.80 | -12.84 | -1.18 |
Annual figures · source: Financial Modeling Prep
ADHERA THERAPEUTICS INC
No one on the platform currently holds ATRX.
No tracked institution reports a position in ATRX as of their last filing.
| Execution date | Ratio |
|---|---|
| 2022-10-06 | 1-for-20reverse |
No one on the platform has traded ATRX yet.
| $575 |
| — |
| IMRSQIMRIS Inc. | $0.00 | +0.00% | $626 | — |
| IMVIFIMV Inc. | $0.00 | +0.00% | $23423 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Fundamental analysis of $ATRX (Adhera Therapeutics, Inc.) based on financial data and reported results. #ATRX #Adhera
View on StockTwits ↗$ATRX Strange as it maybe, I’m guessing that they either sent the files in to late which takes time, or their deadline time was up sending ATRX too the expert market, also maybe Just maybe they did file too late and otc didn’t have the time too see Their file and now wait in turn, However it can can take to September 30 to update So keep an eye out for this company, and let’s hope for the best for company to come threw Otherwise “Neutral “. And disappointed 😡
View on StockTwits ↗$ATRX It’s moved to the expert market Not very good, transfer agent is verified which is very strange, still watching 😡
View on StockTwits ↗$ATRX I have bought in! Novel Efficacious small molacule drug to treat Type 1 Diabetes/NASH. Also a Parkinson's drug.
View on StockTwits ↗$ATRX DTC stock increase, signs of a Something going on good.
View on StockTwits ↗$ATRX Debt gone $640 k cash received in deal. Blue skies ahead. Updated s1 filing coming for uplist?
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.